975P Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial

E.F. Smit, E. Felip, D. Uprety, K. Nakagawa, L. Paz-Ares, J. Pacheco, B.T. Li, D. Planchard, C. Baik, Y. Goto, H. Murakami, A. Saltos, K. Saxena, R. Shiga, Yiji Cheng, Q. Yan, Wentao Feng, P.A. Jänne
Annals of Oncology
September 1, 2022
10.1016/j.annonc.2022.07.1103
Cited by 16

Abstract

Related Papers

No related papers found

Powered by citation graph analysis